Relugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the prevention of pregnancy in women with uterine fibroids or endometriosis.

Relugolix Combination Tablet is not
approved by the FDA in the
prevention of pregnancy.

How it works

As a GnRH receptor antagonist, relugolix binds to and blocks the GnRH receptor in the anterior pituitary gland.

Blocking GnRH receptors decreases the release of gonadotropins – luteinizing hormone (LH) and follicle-stimulating hormone (FSH) – thereby decreasing the downstream production of estrogen and progesterone by the ovaries in women.

You are leaving, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.